Pomegranate extract

Product Name:  Pomegranate extract 
Botanical Source: Punica granatum L.

Part Used: skin or pell
Active Ingredient:
Ellagic Acid: 40%, 50%, 90% HPLC
Polyphenols: 40% UV
Punicalagins 40% HPLC
Appearance: Brown or grey fine powder
Molecular Formula: C14H6O8
Molecular weight: 228.2

 

Pomegranate is a very popular fruit. The fruit of the "Tree of Knowledge" mentioned in the biblical history of creation most probably was meant to be a pomegranate. With a growing history of 2000 years, Megranate is rich in vitamins and minerals. In addition, its husks and seeds are wildly used in Chinese Traditional Medicine. The interior of the pomegranate fruit is composed of many pink-red sections of pulp-like tissue, each of which contains a small seed grain. Pomegranate seeds are collected,dried and processed for medicinal uses.

 

Pomegranate extract main function

(1) Preventing carcinoma of colon, esophageal cancer, liver cancer, lung cancer, etc. 
(2) Enhancing human immunity. 
(3) Sedation and lowering blood pressure.
(4) Owning stronger antioxidation.
(5) Whitening, dispeling spot, anti-wrinkle and delaying skin aging

 

Pomegranate extract Application:

 (1)Applied in pharmaceutical field, it is usually made into capsule to prevent cancer, lower blood pressure and resist oxidation.

(2)Applied in food field, it is usually used as food antioxidants.
(3)Applied in cosmetic field, it mainly used in whitening, dispeling spot, anti-wrinkle and delaying skin aging.

 

For more product information pls contact at email sales09@staherb.cn

 

Specification:

 

Items Standards Results
Physical Analysis    
Description Pink Fine Powder Complies
Assay Ellagic Acid 40% (HPLC)  40.23%
Mesh Size 100 % pass 80 mesh Complies
Ash  5.0% 2.65%
Loss on Drying  5.0% 3.85%
Chemical Analysis    
Heavy Metal  10.0 mg/kg Complies
Pb  2.0 mg/kg Complies
As  1.0 mg/kg Complies
Hg  0.1mg/kg Complies
Microbiological Analysis    
Residue of Pesticide Negative Negative
Total Plate Count  1000cfu/g Complies
Yeast&Mold  100cfu/g Complies
E.coil Negative Negative
Salmonella Negative Negative

References:

 

  1. 1.

    De Pauw-Gillet MC, Houssier C, Fredericq E (1979) Interaction of DNA and purine nucleosides with cis-dichlorodiammineplatinum(II) and antimitotic activity of the complexes on meristematic root cells. Chem Biol Interact 25:87–102

  2. 2.

    Güneri EA, Serbetçiogllu B, Ikiz AO, Güneri A, Ceryan K (2001) TEOAE monitoring of cisplatin induced ototoxicity in guinea pigs: the protective effect of vitamin B treatment. Auris Nasus Larynx 28:9–14

  3. 3.

    Nagy JL, Adelstein DJ, Newman CW, Rybicki LA, Rice TW, Lavertu P (1999) Cisplatin ototoxicity: the importance of baseline audiometry. Am J Clin Oncol 28:305–308

  4. 4.

    Rybak LP, Mukherjea D, Jajoo S, Ramkumar V (2009) Cisplatin ototoxicity and protection: clinical and experimental studies. Tohoku J Exp Med 219(3):177–186

  5. 5.

    Laurell G, Bagger-Sjoback D (1991) Dose-dependent inner ear changes after i.v. administration of cisplatin. J Otolaryngol 20:158–167

  6. 6.

    de Freitas MR, de Castro Brito GA, de Carvalho JV Jr, Gomes RM Jr, Barreto Martins MJ, de Albuquerque Ribeiro R (2009) Light microscopy study of cisplatin-induced ototoxicity in rats. J Laryngol Otol 123(6):590–597

  7. 7.

    Lopez-Gonzalez MA, Guerrero JM, Rojas F, Delgado F (2000) Ototoxicity caused by cisplatin is ameliorated by melatonin and other antioxidants. J Pineal Res 28(2):73–80

  8. 8.

    Daldal A, Odabasi O, Serbetcioglu B (2007) The protective effect of intratympanic dexamethasone on cisplatin-induced ototoxicity in guinea pigs. Otolaryngol Head Neck Surg 137(5):747–752

  9. 9.

    Kalkanis JG, Whitworth C, Rybak LP (2004) Vitamin E reduces cisplatin ototoxicity. Laryngoscope 114(3):538–542

  10. 10.

    Kasse CA, Cruz OL, Iha LC, Costa HO, Lopes EC, Coelho F (2008) The use of Maytenus ilicifolia to prevent cisplatin-induced ototoxicity. Braz J Otorhinolaryngol 74(5):712–717

  11. 11.

    Feghali JG, Liu W, Van De Water TR (2001) L-n-acetyl-cysteine protection against cisplatin-induced auditory neuronal and hair cell toxicity. Laryngoscope 111(7):1147–1155 

  12. 12.

    Lynch ED, Gu R, Pierce C, Kil J (2005) Reduction of acute cisplatin ototoxicity and nephrotoxicity in rats by oral administration of allopurinol and ebselen. Hear Res 201(1–2):81–89

  13. 13.

    Campbell KC, Meech RP, Rybak LP, Hughes LF (1999) D-Methionine protects against cisplatin damage to the stria vascularis. Hear Res 138(1–2):13–28

  14. 14.

    Kelly TC, Whitworth CA, Husain K, Rybak LP (2003) Aminoguanidine reduces cisplatin ototoxicity. Hear Res 186(1–2):10–16

  15. 15.

    Fetoni AR, Quaranta N, Marchese R, Cadoni G, Paludetti G, Sergi B (2004) The protective role of tiopronin in cisplatin ototoxicity in Wistar rats. Int J Audiol 43(8):465–470

  16. 16.

    Huang X, Whitworth CA, Rybak LP (2007) Ginkgo biloba extract (EGb 761) protects against cisplatin-induced ototoxicity in rats. Otol Neurotol 28(6):828–833

  17. 17.

    Teranishi MA, Nakashima T (2003) Effects of trolox, locally applied on round windows, on cisplatin-induced ototoxicity in guinea pigs. Int J Pediatr Otorhinolaryngol 67(2):133–139

  18. 18.

    Malik A, Afaq F, Sarfaraz S, Adhami VM, Syed DN, Mukhtar H (2005) Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer. Proc Natl Acad Sci USA 102(41):14813–14818

  19. 19.

    Esmaillzadeh A, Tahbaz F, Gaieni I, Alavi-Majd H, Azadbakht L (2006) Cholesterol-lowering effect of concentrated pomegranate extract consumption in typeII diabetic patients with hyperlipidemia. Int J Vitam Nutr Res 76:147–151

  20. 20.

    de Nigris F, Williams-Ignarro S, Sica V et al (2007) Effects of a pomegranate fruit extract rich in punicalagin on oxidation-sensitive genes and eNOS activity at sites of perturbed shear stress and atherogenesis. Cardiovasc Res 73:414–423

  21. 21.

    Tugcu V, Kemahli E, Ozbek E et al (2008) Protective effect of a potent antioxidant, pomegranate extract, in the kidney of rats with nephrolithiasis induced by ethylene glycol. J Endourol 22:2723–2731

  22. 22.

    Aviram M, Dornfeld L (2001) Pomegranate extract consumption inhibits serum angiotensin converting enzyme activity and reduces systolic blood pressure. Atherosclerosis 158:195–198

  23. 23.

    Aviram M, Dornfeld L, Kaplan M et al (2002) Pomegranate extract flavonoids inhibit low-density lipoprotein oxidation and cardiovascular diseases: studies in atherosclerotic mice and in humans. Drugs Exp Clin Res 28:49–62

  24. 24.

    Cardinaal RM, Groot JCMJ, Huizing EH, Veldman JE, Smmorenbrg GF (2000) Dose-depend effect of 8-day ciplatin administration upon the morphology of the albino guinea pig cochlea. Hear Res 144:135–146

  25. 25.

    Rybak LP, Whitworth MA, Somani S (1999) Application of antioxidants and other agents to prevent ciplatin ototoxicity. Laryngoscope 109:1740–1744

  26. 26.

    Tzulker R, Glazer I, Bar-Ilan I, Holland D, Aviram M, Amir R (2007) Antioxidant activity, polyphenol content, and related compounds in different fruit juices and homogenates prepared from 29 different pomegranate accessions. J Agric Food Chem 55:9559–9570

  27. 27.

    Viuda-Martos M, Ruiz-Navajas Y, Fernandez-Lopez J, Sendra E, Sayas-Barbera E, Perez-Alvarez JA (2010) Antioxidant properties of pomegranate (Punica granatum L.) bagasses obtained as co-product in the juice extraction. Food Res Int. 

  28. 28.

    Poyrazoglu E, Gökmen V, Artik N (2002) Organic acids and phenolic compounds in pomegranates (Punica granatum L.) grown in Turkey. J Food Compos Anal 15:567–575

  29. 29.

    Fischer UA, Carle R, Kammerer DR (2011) Identification and quantification of phenolic compounds from pomegranates (Punica granatum L.) peel, mesocarp, aril and differently produced juices by HPLC-DAD-ESI/MSn. Food Chem 127:807–821

  30. 30.

    Clerici WJ, DiMartino DL, Prasad MR (1995) Direct effects of reactive oxygen species on cochlear outer hair cell shape in vitro. Hear Res 84:30–40

  31. 31.

    Rybak LP (2007) Mechanisms of cisplatin ototoxicity and progress in otoprotection. Curr Opin Otolaryngol Head Neck Surg 15:364–369

  32. 32.

    De Vita VT Jr (1997) Principles of cancer management: chemotherapy. In: De Vita VT Jr, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 5th edn. Lippincott-Raven, Philadelphia, pp 333–347

  33. 33.

    Rybak LP, Whitworth CA, Mukherjea D, Ramkumar V (2007) Mechanisms of cisplatin-induced ototoxicity and prevention. Hear Res 226(1–2):157–167